加科思-B(01167.HK):完成BET抑制剂JAB-8263用于类风湿关节炎的IIa期临床试验在中国的首例患者给药

智通财经
Jul 27
【加科思-B(01167.HK):完成BET抑制剂JAB-8263用于类风湿关节炎的IIa期临床试验在中国的首例患者给药】智通财经APP讯,加科思-B(01167.HK)发布公告,公司自主研发的BET抑制剂JAB-8263用于类风湿关节炎(RA)的IIa期临床试验在中国完成首例患者给药,标志着JAB-8263正式从肿瘤领域拓展至自身免疫疾病领域,也是全球首个BET抑制剂在RA领域开展的临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10